Inactive Instrument

Fibrocell Science Inc Stock price Nasdaq

Equities

US3157213089

Biotechnology & Medical Research

Dynamic Chart
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index CI
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index CI
Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc.. CI
Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million. CI
Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer CI
Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB CI
Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy CI
Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007 CI
Fibrocell Science, Inc. Auditor Raises 'Going Concern' Doubt CI
Fibrocell Science, Inc. announced that it has received $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm CI
Fibrocell Science, Inc. announced that it expects to receive $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm CI
More news
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
More about the company
  1. Stock
  2. Equities
  3. Stock Fibrocell Science, Inc.
  4. Stock Fibrocell Science Inc - Nasdaq